From left to Right: Prof Roger Ellul-Micallef, Rector Emeritus, Department of Clinical Pharmacology and Therapeutics, Mr Wilfred Kenely, Chief Executive RIDT UoM, Mr Anthony F. Buttigieg, Laboratory Officer, Department of Clinical Pharmacology and Therapeutics, Ms Mirka Pereira, Laboratory Assistant, Department of Clinical Pharmacology and Therapeutics, Prof. Janet Mifsud, Department of Clinical Pharmacology and Therapeutics, Mr Chris Bonello – Sales Executive, Technoline Ltd, Mr Hilary Agius – Sales Manager, Technoline Ltd, Dr Anthony Fenech, Head, Department of Clinical Pharmacology and Therapeutics.

Technoline Ltd, agents for Shimadzu analytical equipment, have donated a new Gas Chromatograph (GC) to the Department of Clinical Pharmacology and Therapeutics of the University of Malta. This equipment is an indispensable tool in the ongoing research projects within the Department, particularly in the monitoring and measurement of drug level in biological samples from patients. The Department conducts such exercises in a range of neurological conditions, particularly in the study of Epilepsy.

Mr Simon Cusens, CEO of Technoline Ltd., stated that this donation is Technoline’s contribution towards the sterling research work that the University of Malta conducts. “We are very pleased that as a company we too can contribute to see the University of Malta increasing its research activities, and we feel proud that through our donation we can one day provide better quality of life to people living with Epilepsy.”

The donation was made through the Research Trust (RIDT) of the University of Malta which has been set up to facilitate public and private donations towards all areas of research within the various departments of the University.

Prof. Janet Mifsud, from the Department of Clinical Pharmacology and Therapeutics emphasised that this donation is of significant benefit in their studies because it will enhance their research potential and will lead to better understanding of pharmacokinetic basis of drug therapy. “This will lead to individualised and better pharmacological therapy for persons and children with difficult to treat Epilepsy” said Prof. Mifsud.